Niagen Bioscience (NAGE) Revenue (2010 - 2026)

Niagen Bioscience (NAGE) has 17 years of Revenue data on file, last reported at $31.5 million in Q1 2026.

• Revenue for Q1 2026 came in at $31.5 million, up 3.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $130.4 million (up 20.84% YoY), and the FY2025 annual result was $129.4 million, up 29.95% from the prior year.
• Revenue declined to $31.5 million in Q1 2026 per NAGE's latest filing, from $33.8 million in the prior quarter.
• Over five years, Revenue peaked at $34.0 million in Q3 2025 and troughed at $16.7 million in Q2 2022.
• A 5-year average of $24.5 million and a median of $22.6 million in 2023 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2025: Revenue slipped 5.46% in 2022, then soared 37.59% in 2025.
• A 5-year view of Revenue shows it stood at $21.0 million in 2022, then advanced by 0.95% to $21.2 million in 2023, then jumped by 37.41% to $29.1 million in 2024, then gained by 16.19% to $33.8 million in 2025, then retreated by 6.99% to $31.5 million in 2026.
• Business Quant data shows NAGE's Revenue at $31.5 million in Q1 2026, $33.8 million in Q4 2025, and $34.0 million in Q3 2025.